These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20701731)

  • 1. Apheresis platelet concentrates contain platelet-derived and endothelial cell-derived microparticles.
    Rank A; Nieuwland R; Liebhardt S; Iberer M; Grützner S; Toth B; Pihusch R
    Vox Sang; 2011 Feb; 100(2):179-86. PubMed ID: 20701731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of platelet microparticles in vivo.
    Rank A; Nieuwland R; Crispin A; Grützner S; Iberer M; Toth B; Pihusch R
    Platelets; 2011; 22(2):111-6. PubMed ID: 21231854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microparticle content of platelet concentrates is predicted by donor microparticles and is altered by production methods and stress.
    Maurer-Spurej E; Larsen R; Labrie A; Heaton A; Chipperfield K
    Transfus Apher Sci; 2016 Aug; 55(1):35-43. PubMed ID: 27470708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-D Rh antibodies appearing after apheresis platelet transfusion: stimulation by red cells or microparticles?
    Kitazawa J; Nollet K; Morioka H; Tanaka K; Inomata M; Kubuki Y; Ohto H
    Vox Sang; 2011 May; 100(4):395-400. PubMed ID: 21029111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced microparticles in ventricular assist device patients predict platelet, leukocyte and endothelial cell activation.
    Diehl P; Aleker M; Helbing T; Sossong V; Beyersdorf F; Olschewski M; Bode C; Moser M
    Interact Cardiovasc Thorac Surg; 2010 Aug; 11(2):133-7. PubMed ID: 20472650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet concentrates, from whole blood or collected by apheresis?
    van der Meer PF
    Transfus Apher Sci; 2013 Apr; 48(2):129-31. PubMed ID: 23535511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet-derived extracellular vesicles in plateletpheresis concentrates as a quality control approach.
    Black A; Pienimaeki-Roemer A; Kenyon O; Orsó E; Schmitz G
    Transfusion; 2015 Sep; 55(9):2184-96. PubMed ID: 26032769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The transfusion of HLA-matched platelets to thrombocytopenic patients resistant to random donor platelets.
    Levy L; Woodfield DG
    N Z Med J; 1984 Oct; 97(766):719-21. PubMed ID: 6595558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A critical comparison of platelet preparation methods.
    Vassallo RR; Murphy S
    Curr Opin Hematol; 2006 Sep; 13(5):323-30. PubMed ID: 16888436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular accumulation of bioactive substances during preparation and storage of various platelet concentrates.
    Edvardsen L; Taaning E; Dreier B; Christensen LD; Mynster T; Nielsen HJ
    Am J Hematol; 2001 Jul; 67(3):157-62. PubMed ID: 11391711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin and platelet count effect on platelet yields in plateletpheresis.
    Guerrero-Rivera S; Gutiérrez-Espíndola G; Talavera JO; Meillón-García LA; Pedraza-Echevarría M; Pizzuto-Chávez J
    Arch Med Res; 2003; 34(2):120-3. PubMed ID: 12700007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
    Pietersz RN
    Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of platelet-derived microparticles in stored apheresis platelet concentrates on polymorphonuclear leucocyte respiratory burst.
    Xie RF; Hu P; Li W; Ren YN; Yang J; Yang YM; Wang ZY; Fan HH
    Vox Sang; 2014 Apr; 106(3):234-41. PubMed ID: 24138005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of platelet concentrates derived by platelet rich plasma, buffy coat and Apheresis.
    Vasconcelos E; Figueiredo AC; Seghatchian J
    Transfus Apher Sci; 2003 Aug; 29(1):13-6. PubMed ID: 12877887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality and safety of platelet apheresis concentrates produced with a new leukocyte reduction system.
    Riggert J; Humpe A; Simson G; Köhler M
    Vox Sang; 1998; 74(3):182-8. PubMed ID: 9595646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H; Seifried E
    Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers.
    Arnold DM; Heddle NM; Kulczycky M; Carruthers J; Sigouin C; Blajchman MA
    Transfusion; 2006 Feb; 46(2):257-64. PubMed ID: 16441604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disparate risks and effects of pooled whole blood-derived vs. apheresis platelet production require an integral view on the blood supply.
    Zimmermann R; Blasczyk R; Zingsem J; Eckstein R; Heuft HG
    Vox Sang; 2010 Oct; 99(3):295-6; author reply 297-8. PubMed ID: 20561324
    [No Abstract]   [Full Text] [Related]  

  • 19. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.
    Janetzko K; Lin L; Eichler H; Mayaudon V; Flament J; Klüter H
    Vox Sang; 2004 May; 86(4):239-45. PubMed ID: 15144528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-derived microparticles are removed by a membrane plasma separator.
    Hanafusa N; Satonaka H; Doi K; Yatomi Y; Noiri E; Fujita T
    ASAIO J; 2010; 56(4):323-5. PubMed ID: 20559139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.